OTCPicks.com: OTCPicks.com Stocks to Watch for Wednesday, November 19th ESNR, SEWC, IDMI, TRXX

Wed. November 19, 2008; Posted: 04:28 AM

Visit http://www.otcpicks.com/smallcap/ to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

ELECTRONIC SENSOR TECHNOLOGY (OTCBB: ESNR | Quote | Chart | News | PowerRating) "Up 185.71% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/ESNR.php

Founded in 1995, Electronic Sensor Technology has developed and patented a chemical vapor analysis process with applications for the homeland security and environment markets.

ESNR News:

November 17 - EST Announces Order for 4 Instruments

Electronic Sensor Technology Inc. (OTCBB: ESNR | Quote | Chart | News | PowerRating) (EST), a leading provider of innovative homeland security and environmental solutions, announced it has received an order for 4 instruments from its distributor in China. The instruments will be used for industrial and security applications.

SEW CAL LOGO INCORPORATED (OTCBB: SEWC | Quote | Chart | News | PowerRating) "Up 100.00% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/SEWC.php

Sew Cal Logo, Inc. produces and manufactures custom embroidered caps, sportswear, and related corporate identification apparel primarily in the United States. It offers caps and headwear, jackets, denim, cargo shorts, pants, and related apparel. The company also provides contract embroidery and silk-screening services to the manufacturing and promotional industry; and designs and manufactures apparel under private labels. In addition, it supplies wardrobe, as well as promotional and cast and crew items for feature films and television. Further, Sew Cal Logo owns the rights to a branded line of surf and sports wear items known as Pipeline Posse, which it sells primarily through the Internet. It sells its products to motion picture and television studios, retailers, local schools, shops, and small businesses. The company was founded in 1985 and is based in Los Angeles, California.

SEWC News:

November 17 - Sew Cal Logo Goes to Hollywood

Sew Cal Logo, Inc. (OTCBB: SEWC | Quote | Chart | News | PowerRating) announced that it recently completed work for the smash hit High School Musical 3. Amongst its other projects, the company will continue to grow this segment of their business. "The entertainment field will likely produce over $3 million in annualized sales," said Rick Songer, company CEO.

New projects in the entertainment segment include: Yes Man (Jim Carrey); The Cheetah Girls; Camp Rock; The Suite Life on Deck; Bone Deep (now filming); Ruby & the Rockits; Chuck; and The Hangover (Warner Bros.). Also, work continues on such popular television productions as CSI Miami, Desperate Housewives and other well known programs as well as special productions.

Adding to the list of Movies and TV shows, the Company has begun work on TRANSFORMERS; REVENGE OF THE FALLEN, sequel to the original blockbuster, which is scheduled to be released this summer. The Company's 20+ year history with the Hollywood entertainment business is expected to grow and add significantly to the bottom line.

Adding to the company's list of achievements, SEW CAL LOGO has received the coveted 2008 Los Angeles Local Business Association Achievement Award (USLBA) as recognition for being the best embroidery business in their local area.

IDM PHARMA INCORPORATED (NASD: IDMI | Quote | Chart | News | PowerRating) "Up 63.87% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/IDMI.php

IDM Pharma, Inc., a biopharmaceutical company, engages in the development of products to treat and control cancer. It develops product candidates to destroy residual cancer cells and to stimulate an immune response and prevent tumor recurrence. The company's products include L-MTP-PE/MEPACT, a Phase 3 clinical trial completed liposomal muramyl-tripeptide phosphatidylethanol- amine, for the treatment of osteosarcoma; BEXIDEM, a Phase 2 clinical trial completed product for the treatment of bladder cancer; UVIDEM, a Phase 2 clinical trial dendritophage and melanoma tumor cell lysates product, for the treatment of melanoma; IDM-2101, a multiple tumor-associated CTL epitopes Phase 2 clinical trial product, for the treatment of non-small cell lung cancer; and COLLIDEM, a Phase 1/2 dendritophages and tumor associated antigen peptides product, for the treatment of colorectal cancer. It has operations in the United States and France. IDM Pharma has collaboration agreements with sanofi-aventis S.A; Medarex, Inc.; GenPharm International, Inc.; Novartis; and Biotecnol S.A. It also has intellectual property licensing and framework agreement with Institut de Recherche Pierre Fabre and Pierre Fabre Medicament S.A. The company was incorporated in 1987 and is based in Irvine, California.

IDMI News:

November 18 - IDM Pharma Receives Recommendation for Approval of Mifamurtide (MEPACT , L-MTP-PE) for the Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma in Europe from the Committee for Medicinal Products for Human Use (CHMP)

IDM Pharma, Inc. (Nasdaq: IDMI | Quote | Chart | News | PowerRating) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion, recommending grant of a centralized marketing authorization for mifamurtide (L-MTP-PE), known as MEPACT in Europe, for the treatment of patients with non-metastatic, resectable osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults. The CHMP recommendation will be adopted at the next CHMP meeting in December with final European Commission approval expected within 60 to 90 days thereafter.

Granting of the centralized marketing authorization will allow L-MTP-PE to be marketed in the 27 Member States of the European Union (EU), as well as in Iceland, Liechtenstein and Norway. L-MTP-PE would be the first approved new treatment in more than 20 years for patients with osteosarcoma. L-MTP-PE was granted orphan medicinal product status in Europe in 2004. Therefore, under European pharmaceutical legislation, L-MTP-PE is entitled to a period of 10 years market exclusivity in respect of the approved indication.

"The recommendation for approval by the CHMP is a great victory for many young patients and their families and is a significant step for the Company in bringing this important treatment to market," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "The Committee's decision validates the clinical trial data and the belief of investigators, patients and IDM Pharma that L-MTP-PE provides a significant overall survival benefit for osteosarcoma patients and meets a significant unmet treatment need."

The positive opinion was based in large part on the Phase 3 L-MTP-PE trial (INT-0133), a National Cancer Institute (NCI) funded cooperative group study conducted by the Children's Oncology Group (COG) and the largest study completed in osteosarcoma, enrolling approximately 800 patients. The study was designed to evaluate patient outcomes with the addition of L-MTP-PE to three- or four-drug adjuvant chemotherapy (cisplatin, doxorubicin, and methotrexate with or without ifosfamide).

Overall survival after six years of follow-up in patients treated with chemotherapy and L-MTP-PE was 78 percent, compared to 70 percent in patients treated with chemotherapy (p=0.03) alone. The addition of L-MTP-PE to chemotherapy resulted in approximately a 30 percent decrease in the risk of death.

Treatment with L-MTP-PE was generally well tolerated in all phases of clinical development. Adverse events were mild to moderate in severity and included chills, fever, nausea, vomiting, myalgia, headache, tachycardia (fast heart rate), hypo- and hypertension, fatigue and shortness of breath, all of which are consistent events with the activation of monocytes and macrophages by L-MTP-PE and the flu-like symptoms that follow cytokine release. These side effects are readily prevented or treated with acetaminophen.

If approved by the European Commission, it is anticipated the Company would conduct certain post-authorization studies or analyses to address follow up questions about L-MTP-PE.

L-MTP-PE U.S. Regulatory Status

As previously announced, in the United States the Company continues to work with the COG as well as external experts and advisors to gather patient follow up data from the Phase 3 clinical trial of L-MTP-PE and to respond to other questions in the non-approvable letter the Company received from the U.S. Food and Drug Administration (FDA). The Company expects to submit the amended New Drug Application (NDA) in the first quarter of 2009 given the recent focus on completing review activities for the Marketing Authorization Application (MAA) in the European Union.

L-MTP-PE was granted orphan drug status in the United States in 2001 and the NDA was submitted to FDA in October 2006 and was accepted for review in December 2006.

ABOUT OSTEOSARCOMA

Between two and three percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with fewer than 1,000 new cases diagnosed in the United States each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group, the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.

TRAXXEC INCORPORATED (OTC: TRXX | Quote | Chart | News | PowerRating) "Up 60.00% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/TRXX.php

Traxxec Inc. (formerly Columbia River Resources Inc.) focuses on RFID packaging solutions and technical support. As part of continuing reorganization, the name change to Traxxec, Inc. became effective from August 11th, 2008. The stock of Traxxec, Inc. is now quoted on the Pink Sheets under ticker symbol "TRXX."

TRXX News:

November 17 - Traxxec, Inc to Provide RFID Packaging in Multi-Billion Dollar Industry

Traxxec, Inc. (OTC: TRXX | Quote | Chart | News | PowerRating) has entered into a fifteen year patent exclusive license agreement with Rexam Plc. (OTC: REXMY) to supply a range of Radio Frequency Identification (RFID) enabled products developed in line with recent guidelines set forth by the US Food and Drug Administration. The product has been marketed by Rexam and exhibited at major corporate events worldwide. Traxxec, Inc who will support Rexam in this agreement had spent more than six years on the development of systems and product prior to licensing and an operational system was first formally presented to the industry at the Barcelona Conference in 2002. Two pilot implementations demonstrated cost benefit by leveraging the technology.

A pharma industry funded project concluded that there was considerable benefit in a container that was more robust and Radio Frequency enabled at source of manufacture. The Traxxec development of its first, such product has been strategically focused on the technical specification and market acceptability. The adoption of RFID in modern, supply chain manufacturing businesses needing to identify and track materials, work in progress and finished goods have shown reductions in manpower costs, reduction in errors and has been used as an anti-counterfeit measure.

Radio Frequency Identification RFID is a mature technology with proven applications. Its key attributes are the ability to carry data in tags, or transponders, which can be attached to items requiring identification, tracking or tracing, "auto-identification" (auto-id). Unlike most other forms of auto-id, RFID enables data to be stored, updated and added to within an individual transponder as well as in a database and this superior capability when combined with increased durability makes the RFID bottle more versatile for auto-identification than, for example, barcodes and labels. In its simplest form, a tag microchip contains a unique identification code that may be read without line of sight by suitable reader/antenna combinations. Pharmaceutical and Packaging News quotes: "the day will come when RFID tags are not applied like a label but are integrated into the material of packaging. The benefit to that is that it will cost less than sticking a label on, and that there is less risk that tags will be damaged, plus, there would be no delay in packaging line speed." That day has arrived with the advent of the Rexam/Traxxec RF enabled bottle.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability:Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details for ESNR click here.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index